Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amrubicin vs Carboplatin/Etoposide in Elderly ED-SCLC
NCT00286169Phase 3Terminated
- Sponsor
- Sumitomo Pharma
- Start
- Apr 2006
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of amrubicin in small cell lung cancer (SCLC), sponsored by Sumitomo Pharma. Started Apr 2006; status: terminated.
02
Drugs
amrubicin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00286169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00286169.